Table 1.
Reported CTCL incidence rates worldwide (rates are denoted as cases per 1 million individuals per year).
| Country | Incidence of CTCL | Incidence of CTCL subtypes | Study year range | Data source | References |
|---|---|---|---|---|---|
| USA | 2.8–10.5 | 1973–2009 | SEER (6,230 patients from Los Angeles, California; San Jose, California; Alaska and rural Georgia) | (11) | |
| USA |
MF = 5.5 SS = 0.1 |
2005–2008 | SEER program (17 data sets representing ~10% of the US population: Connecticut, Hawaii, Iowa, New Mexico, Utah, Detroit, San Francisco/Oakland, Seattle/Puget Sound and Atlanta) | (14) | |
| USA | 6.4 | 1973–2002 | SEER; 13 registries covering ~14% of the US population (Los Angeles and San Jose, California; Alaska; and rural Georgia). | (13) | |
| USA | 7.7 |
MF = 4.1 SS = 0.1 CD30 + LPD = 1.1 SPTC = 0.1 pcPTL = 2.2 |
2001–2005 | 16 SEER registries representing ~26% of the US population (Connecticut, Hawaii, Iowa, Kentucky, Louisiana, New Jersey, New Mexico, and Utah), greater California, rural Georgia, and 6 metropolitan areas (Atlanta, Detroit, Los Angeles, San Francisco–Oakland, San Jose–Monterrey, and Seattle–Puget Sound) | (10) |
| USA | MF 1973–1974 = 1.8 1975–1976 = 2.3 1977–1978 = 2.8 1979–1980 = 2.8 1981–1982 = 4.1 1983–1984 = 4.8 1985–1986 = 4.3 1987–1988 = 4.2 1989–1990 = 4.9 1991–1992 = 4.5 |
1973–92 | SEER (specific states not mentioned) | (15) | |
| Canada | 11.3 | 1992–2010 | Canadian Cancer Registry and Le Registre Québécois du Cancer | (5) | |
| Norway | 1.6 (1980–84) 2.9 (2000–03) |
MF/SS = 1.5–1.8 | 1980–2003 | Cancer Registry of Norway on non-Hodgkin lymphomas | (16) |
| France | 2.0–5.7 | MF = 1.3–2.5 | 1980–2003 | Doubs cancer registry (France) | (17) |
| Kuwait | MF = 4.3 | 1991–2006 | National Dermatology Department (193 patients) | (18) | |
| Wales | 4.8 | 2003–2011 | All Wales Lymphoma Panel (120 Patients) | (19) | |
| Japan | MF/SS = 1.0–1.5 | 2008–2015 | National Cutaneous Lymphoma Registry (391 patients) | (20) |
SEER, Surveillance, Epidemiology, and End Results; MF, mycosis fungoides; SS, Sézary syndrome; CD30+ LPD, CD30+ T-cell lymphoproliferative disorders of the skin; SPTCL, Subcutaneous panniculitis-like T-cell lymphoma; pcPTL, Primary cutaneous peripheral T-cell lymphoma; AITCL, Angioimmunoblastic T-cell lymphoma; MTCL-NOS, Mature T-cell lymphoma NOS; CD30+ALCL, CD30-positive anaplastic large-cell lymphoma; ENKTL-NT, Extranodal NK/T-cell lymphoma, nasal type; ATCLL, Adult T-cell leukemia/lymphoma; EBVANK/TCL, Epstein-Barr virus-associated natural-killer/T-cell lymphoma.